LC3 was found to be related to tumor growth and progression of triple negative breast cancer (22), and be associated with clinical prognosis of pancreatic cancer (23), hepatocellular carcinoma (24) and colorectal cancer (25). Here, MAP1LC3A is linked to neoplasm.